FDA Orphan Drug Designation Awarded to a Myelodysplastic Syndromes Investigative Therapy

Karyopharm Therapeutics has just announced that Eltanexor, their investigative therapy for myelodysplastic syndromes (MDS), has been given Orphan Drug Designation by the FDA. This designation means that the FDA believes…

Continue Reading FDA Orphan Drug Designation Awarded to a Myelodysplastic Syndromes Investigative Therapy
Recent Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes
https://unsplash.com/photos/8rj4sz9YLCI

Recent Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes

An article in PubMed dated October 8, 2021 outlines immune therapies treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients. Both cancers are hematologic malignancies that begin in the…

Continue Reading Recent Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Dr. Richard Stone Discusses Development of Eight Drugs for Acute Myeloid Leukemia Within Four Years
source: pixabay.com

Dr. Richard Stone Discusses Development of Eight Drugs for Acute Myeloid Leukemia Within Four Years

  Dr. Richard Stone recently interviewed with Targeted Oncology to discuss challenging acute myeloid leukemia subtypes and a list of available therapies. Dr. Stone was asked to look back at…

Continue Reading Dr. Richard Stone Discusses Development of Eight Drugs for Acute Myeloid Leukemia Within Four Years
A Case History of a Rheumatologist With Relapsed Leukemia and Triple-Negative Breast Cancer
source: pixabay.com

A Case History of a Rheumatologist With Relapsed Leukemia and Triple-Negative Breast Cancer

Breast cancer is a result of a cell in the breast mutating and multiplying rapidly. There are over 275,000 occurrences of breast cancer in the U.S. each year. However, new…

Continue Reading A Case History of a Rheumatologist With Relapsed Leukemia and Triple-Negative Breast Cancer
Acute Myeloid Leukemia (AML): The Fine Line Between Proliferation of AML Cells and Death Of AML Cells
source: pixabay.com

Acute Myeloid Leukemia (AML): The Fine Line Between Proliferation of AML Cells and Death Of AML Cells

According to a recent article in MedicalXpress, researchers led by professor of medicine Dr. Jing Chen uncovered new data showing how acute myeloid leukemia (AML) becomes active and progresses. The…

Continue Reading Acute Myeloid Leukemia (AML): The Fine Line Between Proliferation of AML Cells and Death Of AML Cells
Phase 3 Data Available on Pevonedistat for AML, MDS, CMML
PhotoLizM / Pixabay

Phase 3 Data Available on Pevonedistat for AML, MDS, CMML

In the Phase 3 PANTHER clinical trial, also known as the Pevonedistat-3001 study, researchers were evaluating pevonedistat in conjunction with azacitidine for patients with acute myeloid leukemia (AML), myelodysplastic syndromes…

Continue Reading Phase 3 Data Available on Pevonedistat for AML, MDS, CMML
The FDA Approves An Expanded Chemotherapy Treatment For Acute Myeloid Leukemia to Include Children
source: pixabay.com

The FDA Approves An Expanded Chemotherapy Treatment For Acute Myeloid Leukemia to Include Children

  Cancer Network recently reported that Jazz Pharmaceuticals’ Vyxeos was approved by the FDA to treat therapy-related pediatric patients one year or older who were newly diagnosed with acute myeloid…

Continue Reading The FDA Approves An Expanded Chemotherapy Treatment For Acute Myeloid Leukemia to Include Children
First Patient Dosed in CA-4948 Trial for Hematologic Malignancies
source: pixabay.com

First Patient Dosed in CA-4948 Trial for Hematologic Malignancies

The first patient has been dosed in a Phase 1 clinical trial, which is exploring Curis Inc.'s CA-4948 in conjunction with ibrutinib for hematologic malignancies. Examples of hematologic malignancies include…

Continue Reading First Patient Dosed in CA-4948 Trial for Hematologic Malignancies